GlassScriptPhysician profile
Alexander Morden
NPI 1528157872
$14,820.43
in general payments reported to CMS, 2019-2025
44 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,523 · 2020: $1,784 · 2021: $2,599 · 2022: $1,852 · 2023: $2,593 · 2024: $2,006 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,928 · Education: $121 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,928.04 |
| Education | $121.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,911.23 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,194.69 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,105.56 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $951.61 | 2019-2021 | |
| Amgen INC. | $765.88 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $622.29 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $596.19 | 2019-2024 | Livalo |
| Novartis Pharmaceuticals Corporation | $570.93 | 2019-2024 | |
| Lilly USA, LLC | $511.47 | 2019-2024 | Mounjaro |
| Abbvie INC. | $473.11 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $443.84 | 2019-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $438.08 | 2019-2025 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $424.05 | 2020-2024 | Trelegy Ellipta |
| Pfizer INC. | $407.23 | 2019-2024 | |
| Allergan, INC. | $326.68 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Morden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.